• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    HERG Screening Companies

    ID: MRFR/HC/8908-CR
    107 Pages
    Kinjoll Dey
    January 2021

    HERG, which stands for the human ether-a-go-go-related gene, is a gene that encodes a potassium ion channel in the heart. Testing or screening for HERG is often related to assessing the potential proarrhythmic effects of drugs, as disruptions in the HERG channel can lead to cardiac arrhythmias, specifically a type known as Torsades de Pointes. Companies involved in HERG screening typically offer services and technologies to assess a drug's impact on HERG channels. These screenings are essential in the drug development process to ensure the safety of new pharmaceuticals.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    HERG Screening Market Research Report - Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the HERG Screening Market

    HERG Screening Key CompaniesDisclaimer: List of key companies in no particular orderLatest HERG screening Companies Update



    • Apr 2023: Evotec SE declared that today marked the grand opening of Cyprotex US, LLC, the company's US site in Framingham, Massachusetts. According to a February announcement by Evotec, Cyprotex US, LLC will move to a new 30,000 square foot facility at 200 Staples Drive in Massachusetts. The newest mass spectrometry and liquid handling automation technologies are featured in Cyprotex's new facility, which translates into notable efficiency gains, increased capacity, and quicker turnaround times. The new facility will provide its partners with a high-throughput option, opening the door for its ADME-Tox services business to grow significantly more for US-based clients.




    • Sep 2023: For the Logica drug platform powered by artificial intelligence (AI), Charles River Laboratories International and Related Sciences (RS) have inked a multi-program partnership agreement. Logica, a system that combines Charles River's preclinical experience with Valo Health's AI-powered Valo Opal Computational Platform, was introduced last year. Logica will be used for several RS portfolio targets that have previously been undrugged. RS will work with the Valo Health and Charles River teams to use Logica to find important new medications. These medications will be utilized to treat unmet needs in immunotherapy for cancer, inflammatory disorders, and autoimmune. Logica leverages Charles River's skills in all areas of discovery optimization in conjunction with Valo's Opal Computational Platform's predictive models, synthesis abilities, chemical design, DNA-encoded libraries, and in silico high throughput screening. Medicinal chemistry, biology, pharmacology, metabolism and excretion, absorption, distribution, and elevated throughput screening are some of these elements.


    List of HERG screening Key companies in the market


    • Charles River Laboratories




    • Eurofins Scientific




    • Merck KGaA




    • Cyprotex Limited




    • BSYS GmbH




    • Creative bioarray




    • Metrion biosciences




    • Aurora Biomed